In 2025, the market for nucleic acid and peptide drug CDMOs reached $5.791 billion, up 29.0% year on year. Demand is expanding for nucleic acid and peptide drugs with high target selectivity in disease areas that are difficult to address with conventional small molecule drugs and antibody drugs.

For nucleic acid drugs, contract services that help reduce manufacturing costs, suppress off target effects, and support commercial production are driving growth. For peptide drugs, demand is increasing for integrated CDMO services that manage synthesis, purification, and formulation as a single process.

This study provides a multifaceted analysis of the business development, business promotion structures, sales, partnerships, and future developments of nucleic acid and peptide drug CDMO companies, with the aim of clarifying market growth factors and the competitive environment.

Research Purpose

In 2025, the market for nucleic acid and peptide drug CDMOs reached $5.791 billion, up 29.0% year on year. Market expansion is driven by growing demand for nucleic acid and peptide drugs with high target selectivity in disease areas that are difficult to address with conventional small molecule drugs and antibody drugs.

In the nucleic acid drug CDMO market, contract services that help solve issues such as reducing manufacturing costs, suppressing off target effects, and supporting commercial production are driving market growth. For example, Nitto Denko manufactures solid phase supports for nucleic acid synthesis internally, thereby reducing raw material costs and cost increases during scale up and providing contract services with high price competitiveness. Ajinomoto uses its AJIPHASE liquid phase hybrid synthesis technology, which reduces reagent and solvent use and improves scale up efficiency, to capture the needs of cost conscious customers.

ST Pharm also provides formulation support using its proprietary STLNP LNP technology and has captured needs for optimizing the delivery of nucleic acid drugs. In addition, Agilent Technologies supports numerous siRNA programs and facilitates the transition from early clinical stages to commercialization.

Meanwhile, the peptide drug CDMO market is expanding against a backdrop of growing demand for integrated CDMO services. One factor is the increasing need for a structure that can manage the processes from synthesis and purification through formulation in an integrated manner as peptide drugs become more sophisticated.

Amid these developments, AmbioPharm provides consistent services from research and development through clinical and commercial production, thereby obtaining contract projects from customers that emphasize quality and development speed. CordenPharma International has entered into a comprehensive partnership from clinical development through commercialization for VK2735, a GLP-1 receptor agonist developed by Viking Therapeutics, and is expanding its business in this field. In addition, Bachem Holding entered into a long term contract in 2022 for peptide supply worth at least CHF 1 billion and has achieved continued sales growth.

Research Scope and Content

This report analyzes nucleic acid and peptide drug CDMO companies from multiple perspectives, including each company's business development status, business promotion structure, sales trends, partnership status, and future developments. Its purpose is to clarify market growth factors and the competitive environment and provide insights that contribute to the expansion of nucleic acid and peptide drug CDMO businesses.

Research Period

December 2025 to April 2026

Format

A4 size, 160 pages

Publication Date

April 21, 2026

Tabulation and Analysis Section

• 1. Research Overview
  • 1-1. Research Objective
  • 1-2. Scope of Research
• 2. Business Development Status
• 3. Business Promotion Structure
  • 3-1. Business Promotion Sites
  • 3-2. Production Facilities Status
• 4. Market Trends in Nucleic Acid and Peptide Drug CDMOs
  • 4-1. Overall
  • 4-2. By Type
  • 4-3. By Region
  • 4-4. By Company
  • 4-5. By Type and Company
  • 4-6. By Region and Company
• 5. Partnership Status
• 6. Future Market Prospects
  • 6-1. Market Forecast
  • 6-2. Future Developments of Major Companies

Individual Company Section

• Agilent Technologies
• AmbioPharm
• Bachem Holding
• BioSpring
• CordenPharma International
• EUROAPI
• PolyPeptide Group
• ST Pharm
• WuXi AppTec
• Ajinomoto
• Nitto Denko
• Peptide Star
• Aurigene Pharmaceutical Services
• Kaneka
• Nippon Shokubai
• Peptide Institute

Survey Items (Individual Company Section)

• 1. Business Development Status
• 2. Business Promotion Structure
  • 2-1. Nucleic Acid and Peptide Drug CDMO Sites
  • 2-2. Production Facilities Status
• 3. Sales of Nucleic Acid and Peptide Drug CDMOs
  • 3-1. By Type
  • 3-2. By Region
• 4. Partnership Status
• 5. Future Developments